GoAI
Get started
Modern Chinese Medicine Group Co., Ltd. logo

Modern Chinese Medicine Group Co., Ltd.

1643.HK

HKSEHealthcareMedical - Pharmaceuticals

Open in GoAI

Latest quote

HK$0.85

+HK$0.03 · +3.66%

Aug 21, 3:53 PM HKTData delayed

1643.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

As an investment holding company, Modern Chinese Medicine Group Co., Ltd. manufactures and distributes traditional Chinese pharmaceutical products, primarily targeting the middle-aged and elderly populations across the People's Republic of China. Its extensive product line provides treatments for a wide array of health issues, including qi deficiency, blood stasis, cardiovascular and cerebrovascular conditions, digestive and gastrointestinal ailments, gynecological problems, as well as disorders affecting the respiratory and nervous systems. Established in 1986, the enterprise maintains its principal offices in Chengde, China, and operates as a subsidiary of Modern Biotechnology Group Holdings Co., Ltd.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
CN
CEO
Hongli Zhang
Listed since
Jan 15, 2021
Employees
189

Market position

52-week range

Current HK$0.85

Open
HK$0.85
Previous close
HK$0.82
Volume
618K
0.58× average
Average volume
1.07M
Average daily volume
Market cap
612M HKD
Beta
0.19
Market reference 1
50-day average
HK$1.0388
-18.17% below average
200-day average
HK$1.3624
-37.61% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-35.85×
P/B (TTM)
0.95×
P/S (TTM)
3.64×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
16.22%
Operating margin
-11.40%
Net margin
-9.24%

Financial health

Debt / equity
0×
Altman Z-score
8.91
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends49%27%5%-17%Gross margin, FY2021: 43.92%Gross margin, FY2022: 42.73%Gross margin, FY2023: 30.28%Gross margin, FY2024: 25.78%Gross margin, FY2025: 16.07%Operating margin, FY2021: 28.59%Operating margin, FY2022: 31.55%Operating margin, FY2023: 19.43%Operating margin, FY2024: 10.43%Operating margin, FY2025: -11.30%Net margin, FY2021: 22.67%Net margin, FY2022: 21.98%Net margin, FY2023: 14.18%Net margin, FY2024: 4.52%Net margin, FY2025: -9.34%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 43.92%. Gross margin FY2022 42.73%. Gross margin FY2023 30.28%. Gross margin FY2024 25.78%. Gross margin FY2025 16.07%. Operating margin FY2021 28.59%. Operating margin FY2022 31.55%. Operating margin FY2023 19.43%. Operating margin FY2024 10.43%. Operating margin FY2025 -11.30%. Net margin FY2021 22.67%. Net margin FY2022 21.98%. Net margin FY2023 14.18%. Net margin FY2024 4.52%. Net margin FY2025 -9.34%.

Income trends

Revenue

141.42M CNY-33.94%

Operating income

−15.97M CNY−38.3M CNY

Net income

−13.21M CNY−22.88M CNY
Income trends across reported periods441.22M CNY274.97M CNY108.71M CNY−57.54M CNYRevenue, FY2021: 360.7M CNYRevenue, FY2022: 399.66M CNYRevenue, FY2023: 344.08M CNYRevenue, FY2024: 214.07M CNYRevenue, FY2025: 141.42M CNYOperating income, FY2021: 103.14M CNYOperating income, FY2022: 126.1M CNYOperating income, FY2023: 66.87M CNYOperating income, FY2024: 22.33M CNYOperating income, FY2025: −15.97M CNYNet income, FY2021: 81.78M CNYNet income, FY2022: 87.83M CNYNet income, FY2023: 48.8M CNYNet income, FY2024: 9.67M CNYNet income, FY2025: −13.21M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 360.7M CNY. Revenue FY2022 399.66M CNY. Revenue FY2023 344.08M CNY. Revenue FY2024 214.07M CNY. Revenue FY2025 141.42M CNY. Operating income FY2021 103.14M CNY. Operating income FY2022 126.1M CNY. Operating income FY2023 66.87M CNY. Operating income FY2024 22.33M CNY. Operating income FY2025 −15.97M CNY. Net income FY2021 81.78M CNY. Net income FY2022 87.83M CNY. Net income FY2023 48.8M CNY. Net income FY2024 9.67M CNY. Net income FY2025 −13.21M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue141.42M CNY214.07M CNY344.08M CNY399.66M CNY360.7M CNY
Cost of goods sold118.69M CNY158.87M CNY239.9M CNY228.87M CNY202.27M CNY
Gross profit22.73M CNY55.2M CNY104.18M CNY170.79M CNY158.43M CNY
Research and development—1.5M CNY1.5M CNY3M CNY10.5M CNY
Selling, general, and administrative40.1M CNY31.37M CNY35.81M CNY41.69M CNY44.79M CNY
Operating expenses38.71M CNY32.87M CNY37.31M CNY44.69M CNY55.29M CNY
Interest income695.52K CNY766K CNY906K CNY675K CNY421K CNY
Interest expense5.84K CNY1K CNY5K CNY14K CNY74K CNY
Depreciation and amortization11.35M CNY6M CNY6.44M CNY5.69M CNY2.72M CNY
Operating income−15.97M CNY22.33M CNY66.87M CNY126.1M CNY103.14M CNY
Net income−13.21M CNY9.67M CNY48.8M CNY87.83M CNY81.78M CNY

Company facts updated Aug 24, 2026.

Corporate actions

Corporate action history

Dividend

Ex-dividend May 25, 2022

HK$0.0167

Special

Record May 26, 2022 · Payment Jun 13, 2022

1643.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$195.4

-5.05%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.50

-3.53%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$220.2

-3.42%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.30

-5.29%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$98.90

-3.42%

Continue in GoAI

Research 1643.HK

research.disclaimer